Credit Suisse Assumes, Downgrades Esperion Therapeutics (ESPR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Esperion Therapeutics (ESPR) a Top Pick at UBS Into 2nd-Half; Buy on Weakness
June 24, 2015 8:49 AM EDTUBS analyst Andrew Peters is reiterating a Buy rating and $140 price target on Esperion Therapeutics (NASDAQ: ESPR) while naming it a top pick heading into the 2nd-half. The firm views the recent pullback as an opportunity ahead of meaningful near-term catalysts.
"Notably our... More
Esperion Therapeutics (ESPR) Reconfirmed Timelines for Upcoming Catalysts, JMP Securities Notes
June 24, 2015 8:40 AM EDTJMP Securities reiterated a Market Outperform rating and $177 price target on Esperion Therapeutics (NASDAQ: ESPR) after CEO Tim Mayleben reconfirmed timelines for upcoming catalysts.
The analyst highlighted:
The 014 study results are expected in the second half of next month, an... More